Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

411 currently recruiting clinical trials
Region Provence-Alpes-Côte d'Azur

Phase 3 Endometrial cancer #NCT06340568 #2023-507525-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
8 recruiting sites
BioNTech SE
Phase 3 Breast cancer #NCT06380751
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRCA 1/2 PALB2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Stomach and esophageal cancer #NCT07043400 #2025-522862-58-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
HER2
3 recruiting sites
BeOne Medecines
Phase 3 Endometrial cancer #NCT06712472 #2023-503886-44-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required FIGO stages
Stage I Stage II Stage III
Required disease stage
Localized Locally Advanced
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
MSI/dMMR POLE
14 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Prostate cancer #NCT06952803 #2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy
20 recruiting sites
AstraZeneca
Phase 3 Liver and bile duct cancer #NCT06467357 #2023-508057-19-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC)
8 recruiting sites
AstraZeneca
Phase 3 Endometrial cancer #NCT06989112 #2023-508056-19-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Phase 3 Lung cancer #NCT06417814 #2024-511362-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
14 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT05952557 #2023-504031-41-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
21 recruiting sites
AstraZeneca
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06919965
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy
7 recruiting sites
Janssen